.jetcityimage/iStock Editorial by means of Getty Images Morgan Stanley has opted for Eli Lilly (NYSE: LLY) as its own leading biopharma choice for 2025 as well as rated an additional 9 names in the room as overweight. The assets banking company stated in a details that it remains to believe “diabesity is readied to end up being.